Who May Be at Risk for Gastroparesis with Ozempic?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Literacy to Targeted Drug Safety

If you are taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering about the risk of gastroparesis. Decades of pharmacovigilance have established that medications can sometimes affect gastric motility, and recent reports have raised specific concerns about GLP-1 receptor agonists. This page reviews the FDA warning, who may be at higher risk, and what the long-term outlook looks like based on current evidence.

Clinical Evidence Linking Ozempic to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its prescribing information documents a range of gastrointestinal adverse reactions, which are among the most commonly reported side effects. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, has been associated with GLP-1 receptor agonists, including Ozempic, through both clinical trial data and post-marketing surveillance. Clinical presentation of gastroparesis typically includes early satiety, postprandial fullness, nausea, vomiting, bloating, and abdominal pain. Diagnosis is confirmed through gastric emptying scintigraphy or other motility studies. The symptoms overlap significantly with the gastrointestinal adverse reactions listed in Ozempic's prescribing information. In placebo-controlled trials, nausea occurred in 15.8% of patients receiving Ozempic 0.5 mg and 20.3% of those receiving 1 mg, compared to 6.1% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Vomiting was reported in 5.0% and 9.2% of patients on 0.5 mg and 1 mg, respectively, versus 2.3% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Diarrhea, abdominal pain, and constipation were also more frequent in Ozempic-treated groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These adverse reactions were most common during dose escalation, and discontinuation due to gastrointestinal issues occurred in 3.1% of patients on 0.5 mg and 3.8% on 1 mg, compared to 0.4% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathway and Risk Considerations

The mechanistic pathway linking Ozempic to gastroparesis involves the drug's action on GLP-1 receptors in the gastrointestinal tract. GLP-1 receptor agonists slow gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to delayed gastric emptying and symptoms consistent with gastroparesis. This pharmacological effect is dose-dependent and may persist with continued use. The prescribing information does not explicitly list gastroparesis as a separate adverse reaction but includes nausea, vomiting, and abdominal pain as common events (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Serious adverse reactions such as pancreatitis, acute kidney injury, and acute gallbladder disease are noted, but gastroparesis is not specifically mentioned (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Risk considerations for patients include the adequacy of warnings regarding the potential for gastroparesis. The prescribing information highlights gastrointestinal adverse reactions as common but does not provide explicit guidance on monitoring for gastroparesis or its management. For affected patients, causation considerations involve the temporal relationship between Ozempic initiation and symptom onset. In clinical trials, gastrointestinal symptoms typically emerged during dose escalation, suggesting a dose-dependent effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the timeline for documented harm in post-marketing reports may vary, with some patients experiencing symptoms after prolonged use. The absence of a specific warning for gastroparesis may lead to underrecognition of the condition, particularly in patients with pre-existing gastrointestinal disorders. Causation-related considerations for affected patients include the need to differentiate drug-induced gastroparesis from other causes, such as diabetic gastroparesis, which is common in the type 2 diabetes population. The overlap in symptoms complicates attribution. Patients who develop persistent nausea, vomiting, or abdominal pain after starting Ozempic should be evaluated for gastroparesis, and discontinuation of the drug may be considered if symptoms are severe. The prescribing information notes that gastrointestinal adverse reactions led to discontinuation in a small percentage of patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but this does not capture all cases of gastroparesis that may resolve after stopping the drug. In summary, the evidence from clinical trials and prescribing information supports a plausible link between Ozempic and gastroparesis through the drug's known effect on gastric motility. The adequacy of current warnings is limited by the absence of explicit mention of gastroparesis, despite the high frequency of gastrointestinal symptoms. Patients and clinicians should be aware of this potential adverse effect, particularly during dose escalation, and consider monitoring for signs of delayed gastric emptying. Further research is needed to clarify the incidence, risk factors, and long-term outcomes of Ozempic-associated gastroparesis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning about Ozempic and gastroparesis?

The FDA has not issued a specific warning for gastroparesis with Ozempic, but the prescribing information lists gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain, which are common. Post-marketing surveillance has reported cases of gastroparesis associated with GLP-1 receptor agonists, including Ozempic. The FDA continues to monitor these events.

How is Ozempic-related gastroparesis diagnosed?

Diagnosis of gastroparesis is confirmed through gastric emptying scintigraphy or other motility studies. Symptoms include early satiety, postprandial fullness, nausea, vomiting, bloating, and abdominal pain. It is important to differentiate drug-induced gastroparesis from other causes, such as diabetic gastroparesis, which is common in the type 2 diabetes population.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.